WO2006004390A3 - Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína - Google Patents

Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína Download PDF

Info

Publication number
WO2006004390A3
WO2006004390A3 PCT/MX2005/000049 MX2005000049W WO2006004390A3 WO 2006004390 A3 WO2006004390 A3 WO 2006004390A3 MX 2005000049 W MX2005000049 W MX 2005000049W WO 2006004390 A3 WO2006004390 A3 WO 2006004390A3
Authority
WO
WIPO (PCT)
Prior art keywords
morphine
against morphine
preparation
heroin addiction
vaccine against
Prior art date
Application number
PCT/MX2005/000049
Other languages
English (en)
French (fr)
Other versions
WO2006004390A2 (es
Inventor
Palma Benito Anton
Gelman Philippe Leff
Original Assignee
Te Muniz Inst Nac De Psiquiatr
Palma Benito Anton
Gelman Philippe Leff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0513024-7A priority Critical patent/BRPI0513024A/pt
Priority to CA2573042A priority patent/CA2573042C/en
Priority to SI200531802T priority patent/SI1767221T1/sl
Priority to DK05761917.3T priority patent/DK1767221T3/da
Priority to EP05761917.3A priority patent/EP1767221B1/en
Priority to US11/632,085 priority patent/US8008457B2/en
Priority to ES05761917T priority patent/ES2435769T3/es
Priority to PL05761917T priority patent/PL1767221T3/pl
Application filed by Te Muniz Inst Nac De Psiquiatr, Palma Benito Anton, Gelman Philippe Leff filed Critical Te Muniz Inst Nac De Psiquiatr
Publication of WO2006004390A2 publication Critical patent/WO2006004390A2/es
Publication of WO2006004390A3 publication Critical patent/WO2006004390A3/es
Priority to CU2007000002A priority patent/CU23917B1/es
Priority to US13/182,634 priority patent/US8357375B2/en
Priority to US13/709,507 priority patent/US8916170B2/en
Priority to US14/535,007 priority patent/US20150064212A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/141111—Diverse hetero atoms in same or different rings [e.g., alkaloids, opiates, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se revela el diseño estructural, métodos de preparación y composición química de dos formulaciones estructurales de vacunas bivalentes contra la adicción a morfina-heroína (morfina-6-hemiscuccinil-EDC-TFCS-toxoide tetánico y 3-0-carboximetilmorfina-EDC-TFCS-toxoide tetánico), adecuados para su empleo en la vacunación en el humano, los cuales son capaces de inducir la síntesis de anticuerpos policlonales contra este opiáceo adictivo y contra su análogo estructural la heroína, a través de su administración repetida in vivo, en un esquema de vacunación activa en estudios de fase preclínica en el modelo animal del roedor.
PCT/MX2005/000049 2004-07-07 2005-07-05 Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína WO2006004390A2 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES05761917T ES2435769T3 (es) 2004-07-07 2005-07-05 Preparación y utilización de una vacuna bivalente contra la adicción a la morfina y la heroína
SI200531802T SI1767221T1 (sl) 2004-07-07 2005-07-05 Priprava in uporaba dvovalentnega cepiva proti odvisnosti od morfina-heroina
DK05761917.3T DK1767221T3 (da) 2004-07-07 2005-07-05 Tilberedning og anvendelse af en divalent vaccine mod morfin/heroin-afhængighed
EP05761917.3A EP1767221B1 (en) 2004-07-07 2005-07-05 Preparation and use of a bivalent vaccine against morphine-heroine addiction
US11/632,085 US8008457B2 (en) 2004-07-07 2005-07-05 Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction
BRPI0513024-7A BRPI0513024A (pt) 2004-07-07 2005-07-05 processo para a preparação e uso de uma vacina bivalente contra vìcio de morfina-heroìna
PL05761917T PL1767221T3 (pl) 2004-07-07 2005-07-05 Wytwarzanie i zastosowanie biwalentnej szczepionki przeciwko uzależnieniu od morfiny-heroiny
CA2573042A CA2573042C (en) 2004-07-07 2005-07-05 Process for the preparation and use of a bivalent vaccine against morphine-heroin addiction
CU2007000002A CU23917B1 (es) 2004-07-07 2007-01-05 Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína
US13/182,634 US8357375B2 (en) 2004-07-07 2011-07-14 Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction
US13/709,507 US8916170B2 (en) 2004-07-07 2012-12-10 Methods of producing antibodies against morphine-heroine
US14/535,007 US20150064212A1 (en) 2004-07-07 2014-11-06 Process for the preparation and use of a bivalent vaccine against morphine-heroin addiction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MXPA04006617A MXPA04006617A (es) 2004-07-07 2004-07-07 Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
MXPA/A/2004/006617 2004-07-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/632,085 A-371-Of-International US8008457B2 (en) 2004-07-07 2005-07-05 Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction
US13/182,634 Division US8357375B2 (en) 2004-07-07 2011-07-14 Process for the preparation and use of a bivalent vaccine against morphine-heroine addiction

Publications (2)

Publication Number Publication Date
WO2006004390A2 WO2006004390A2 (es) 2006-01-12
WO2006004390A3 true WO2006004390A3 (es) 2006-09-21

Family

ID=35431510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2005/000049 WO2006004390A2 (es) 2004-07-07 2005-07-05 Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína

Country Status (15)

Country Link
US (4) US8008457B2 (es)
EP (1) EP1767221B1 (es)
AR (1) AR049962A1 (es)
BR (1) BRPI0513024A (es)
CA (1) CA2573042C (es)
CU (1) CU23917B1 (es)
CY (1) CY1114673T1 (es)
DK (1) DK1767221T3 (es)
ES (1) ES2435769T3 (es)
MX (1) MXPA04006617A (es)
PE (1) PE20060377A1 (es)
PL (1) PL1767221T3 (es)
PT (1) PT1767221E (es)
SI (1) SI1767221T1 (es)
WO (1) WO2006004390A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.
US8170546B2 (en) 2006-03-22 2012-05-01 Broadcom Corporation Client device characterization of other client device transmissions and reporting of signal qualities to access point(s)
EP1982729A1 (en) * 2007-04-20 2008-10-22 Cytos Biotechnology AG Vaccination Regimen for B-Cell Vaccines
WO2011041483A2 (en) * 2009-09-30 2011-04-07 Toxcure, Inc. Use of botulinum neurotoxin to treat substance addictions
CN102002049B (zh) * 2010-10-12 2013-01-02 北京大学 一种抗原及其制备方法与应用
CN102539764A (zh) * 2010-12-27 2012-07-04 北京库尔科技有限公司 盐酸哌替啶检测试剂盒及其制备方法
EP2717057A1 (en) * 2012-10-04 2014-04-09 Cisbio Bioassays Morphine-6-glucuronide derivatives, immunogens and immunoassay
RU2526807C2 (ru) * 2012-11-28 2014-08-27 Общество с ограниченной ответственностью "ДИАМЕДИКА" ООО "ДИАМЕДИКА" Синтетический иммуноген для защиты от токсического действия наркотических и психоактивных веществ
EP2970320B1 (en) 2013-03-15 2020-10-28 Johnson Matthey Public Limited Company Morphine sulfate methanolic solvate, processes for making same and related compositions and methods for treating pain
US10262505B1 (en) * 2013-12-03 2019-04-16 Ca, Inc. Anti-skimming solution
CN108884127A (zh) 2016-01-21 2018-11-23 斯克利普斯研究院 合成的阿片类疫苗
US11660331B2 (en) 2017-11-09 2023-05-30 The Scripps Research Institute Heroin vaccine
WO2020012245A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Thienothiophene-naltrexone prodrugs for long-acting injectable compositions
WO2020012248A1 (en) 2018-07-13 2020-01-16 Alkermes Pharma Ireland Limited Novel naphthylenyl compounds for long-acting injectable compositions and related methods
WO2020094634A1 (en) 2018-11-05 2020-05-14 Alkermes Pharma Ireland Limited Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods
RU2703494C1 (ru) * 2018-11-12 2019-10-18 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело 6g1 к производным морфина

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003163A1 (de) * 1990-08-22 1992-03-05 Cerny Erich H Impfstoff und immunserum gegen drogen
WO1996030049A2 (en) * 1995-03-31 1996-10-03 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy
WO1998014216A2 (en) * 1996-09-30 1998-04-09 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CN1196955A (zh) * 1998-04-24 1998-10-28 昆明市生物技术工程研究中心 人用阿片类毒品戒毒疫苗
WO2004076677A2 (en) * 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6210677B1 (en) * 1993-01-29 2001-04-03 Robert C. Bohannon Method to reduce the physiologic effects of drugs on mammals
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
MXPA04006617A (es) 2004-07-07 2006-01-12 Inst Nac De Psiquiatria Ramon Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroina.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003163A1 (de) * 1990-08-22 1992-03-05 Cerny Erich H Impfstoff und immunserum gegen drogen
WO1996030049A2 (en) * 1995-03-31 1996-10-03 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy
WO1998014216A2 (en) * 1996-09-30 1998-04-09 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
CN1196955A (zh) * 1998-04-24 1998-10-28 昆明市生物技术工程研究中心 人用阿片类毒品戒毒疫苗
WO2004076677A2 (en) * 2003-02-26 2004-09-10 Institute For Research In Biomedicine Monoclonal antibody production by ebv transformation of b cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"MORPHINE-3-SUCCINYL-BOVINE SERUM ALBUMIN: AN IMMUNOGENIC HAPTEN-PROTEIN CONJUGATE", SCIENCE, vol. 176, 1972, pages 1143 - 1145, XP008063062 *
AKBARZADEH A. ET AL: "Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development", BIOTECHNOL. APPL. BIOCHEM., vol. 30, 1999, pages 139 - 145, XP008062993 *
ANONYMOUS: "TFCS 22299: TFCS, N-(e-Trifluoroacetylcaproyloxy)succinimide ester", INTERNET ARTICLE, XP002386871, Retrieved from the Internet <URL:http://www.piercenet.com/> [retrieved on 20060418] *
CARRERA R. A.: "A second-generation vaccine protects against the psychoactive effects of cocaine", PNAS, vol. 98, February 2001 (2001-02-01), pages 1988 - 1992, XP008063031 *
GEBHART G. F.: "Morphine-6-hemisuccinate as a narcotic analgesic", LIFE SCIENCE, vol. 18, 1976, pages 829 - 836, XP008062987 *
HEADING C. E.: "TA-CD Xenova", IDRUGS, vol. 5, 2002, pages 1070 - 1074, XP008062988 *

Also Published As

Publication number Publication date
WO2006004390A2 (es) 2006-01-12
US20130236478A1 (en) 2013-09-12
CY1114673T1 (el) 2016-10-05
US20150064212A1 (en) 2015-03-05
CA2573042C (en) 2013-01-15
PL1767221T3 (pl) 2014-02-28
CU20070002A7 (es) 2009-09-08
US8357375B2 (en) 2013-01-22
MXPA04006617A (es) 2006-01-12
BRPI0513024A (pt) 2008-04-22
SI1767221T1 (sl) 2014-01-31
PT1767221E (pt) 2013-11-27
PE20060377A1 (es) 2006-05-05
CA2573042A1 (en) 2006-01-12
US8008457B2 (en) 2011-08-30
US20110318381A1 (en) 2011-12-29
CU23917B1 (es) 2013-07-31
EP1767221B1 (en) 2013-08-21
DK1767221T3 (da) 2013-11-25
ES2435769T3 (es) 2013-12-23
EP1767221A2 (en) 2007-03-28
AR049962A1 (es) 2006-09-20
US8916170B2 (en) 2014-12-23
US20080241183A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2006004390A3 (es) Proceso para la preparación y uso de una vacuna bivalente contra la adicción a la morfina-heroína
NO20015073D0 (no) Vaksiner
WO2005097211A3 (en) Compositions as adjuvants to improve immune responses to vaccines and methods of use
WO2005105140A3 (en) Meningococcal conjugate vaccination
WO2007022151A3 (en) Immunization of avians by administration of non-replicating vectored vaccines
GB0500787D0 (en) Integration of meningococcal conjugate vaccination
WO2008057235A3 (en) Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes
WO2005065318A3 (en) Effervescent oral opiate dosage form
WO2004089299A3 (en) Pulsatile transdermally administered antigens and adjuvants
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
WO2006113622A3 (en) Direct vaccination of the bone marrow
WO2004103400A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
WO2006034320A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2006026689A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2011038397A3 (en) Peptide adjuvants, vaccines, and methods of use
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2005007804A3 (en) Anthrax conjugate vaccine and antibodies
WO2004006831A3 (en) Method and device for inducing biological processes by micro-organs
MY127452A (en) Vaccines.
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
WO2008063555A3 (en) Methods of enhancing immune response using electroporation-assisted vaccination and boosting
WO2004058806A3 (en) Inclusion bodies as antigens for the oral vaccination of animals against csfv
MX346303B (es) Proceso para la preparacion y uso de una vacuna bivalente contra la adiccion a la morfina-heroína.
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use
ZA200202511B (en) A process for the preparation of a vaccine for the treatment of tuberculosis and other intracellular infections diseases and the vaccine produced by the process.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2573042

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005761917

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005761917

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11632085

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0513024

Country of ref document: BR